GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...

OPEN The FTSE 100 was expected to open 38.4 points lower ahead of the bell on Friday after closing 0.23% higher in the ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker’s application to expand the use of ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The shot is approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. Read more at straitstimes.com. Read more at straitstimes.com.

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...